Statements (62)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:monoclonal_antibody
|
| gptkbp:administered_by |
intravenous infusion
|
| gptkbp:approves |
gptkb:2011
gptkb:FDA |
| gptkbp:brand |
gptkb:Benlysta
|
| gptkbp:chemical_formula |
C646 H1008 N178 O198 S4
|
| gptkbp:clinical_trial |
Phase III
BLISS-NEO BLISS-52 BLISS-76 |
| gptkbp:clinical_use |
immunosuppressive therapy
|
| gptkbp:contraindication |
active infections
hypersensitivity to belimumab |
| gptkbp:developed_by |
Human Genome Sciences
|
| gptkbp:dosage_form |
lyophilized powder for reconstitution
|
| gptkbp:drug_interactions |
live vaccines
other immunosuppressants |
| gptkbp:financial_stability |
24 months
|
| gptkbp:formulation |
intravenous solution
subcutaneous solution |
| https://www.w3.org/2000/01/rdf-schema#label |
Belimumab
|
| gptkbp:indication |
gptkb:rheumatoid_arthritis
gptkb:dermatomyositis lupus nephritis |
| gptkbp:invention |
2026
|
| gptkbp:market_approval |
gptkb:Australia
gptkb:Canada gptkb:Japan gptkb:EU |
| gptkbp:marketed_as |
gptkb:Glaxo_Smith_Kline
|
| gptkbp:mechanism_of_action |
inhibits B-lymphocyte stimulator
|
| gptkbp:patient_education |
monitor for signs of infection
report mood changes |
| gptkbp:patient_population |
adults
children over 5 years |
| gptkbp:pharmacokinetics |
long half-life
reduces autoantibody production |
| gptkbp:provides_guidance_on |
EULAR recommendations
ACR guidelines |
| gptkbp:research |
combination therapy with other agents
long-term safety profile efficacy in pediatric patients |
| gptkbp:research_areas |
autoimmune diseases
|
| gptkbp:route_of_administration |
subcutaneous injection
|
| gptkbp:safety_measures |
post-marketing surveillance
|
| gptkbp:service_frequency |
every 4 weeks
initially every 2 weeks |
| gptkbp:side_effect |
gptkb:depression
fatigue headache nausea increased risk of infections anaphylaxis infusion reactions |
| gptkbp:storage |
2 to 8 ° C
|
| gptkbp:targets |
B cells
|
| gptkbp:treatment |
improved disease activity
reduced corticosteroid use |
| gptkbp:used_for |
gptkb:systemic_lupus_erythematosus
|
| gptkbp:weight |
144 k Da
|
| gptkbp:bfsParent |
gptkb:EMD_Serono
|
| gptkbp:bfsLayer |
5
|